Draft NICE guidance does not recommend Aimovig in migraine.- Novartis.
In draft guidelines, the National Institute for Health and Care Excellence (NICE) has announced that it has decided that Aimovig (erenumab), from Novartis, cannot be funded by the NHS as preventative treatment for migraine. Aimovig was approved for use in Europe last year as the first treatment specifically designed to prevent migraine.
The EU approval is based on the phase IIIb LIBERTY trial, which assessed Aimovig in episodic migraine patients who had previously tried two to four therapies without success, showing that patients taking the drug had almost three-fold higher odds of having migraine days cut by half or more versus placebo. More than twice as many patients taking Aimovig achieved this reduction.
However, NICE argued that the evidence from the LIBERTY trial doesn�t fully reflect patients seen in clinical practice in the NHS and nor does it include all the relevant comparators and outcomes. The result of this is that cost-effectiveness estimates for the drug are higher than those normally considered acceptable.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
2 mins